Citigroup Inc. Has $1.23 Million Position in Karyopharm Therapeutics Inc (KPTI)

Citigroup Inc. boosted its position in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 1,125.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 130,817 shares of the company’s stock after purchasing an additional 120,143 shares during the period. Citigroup Inc. owned about 0.22% of Karyopharm Therapeutics worth $1,226,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in KPTI. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Karyopharm Therapeutics by 71.7% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 68,835 shares of the company’s stock valued at $645,000 after purchasing an additional 28,745 shares during the last quarter. California Public Employees Retirement System increased its holdings in shares of Karyopharm Therapeutics by 391.0% in the fourth quarter. California Public Employees Retirement System now owns 165,746 shares of the company’s stock valued at $1,553,000 after purchasing an additional 131,986 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after purchasing an additional 3,300 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $1,576,000. Finally, Prudential Financial Inc. increased its holdings in shares of Karyopharm Therapeutics by 233.9% in the fourth quarter. Prudential Financial Inc. now owns 73,530 shares of the company’s stock valued at $689,000 after purchasing an additional 51,510 shares during the last quarter. 84.81% of the stock is owned by hedge funds and other institutional investors.

KPTI stock opened at $4.71 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.13 and a current ratio of 7.13. Karyopharm Therapeutics Inc has a 52 week low of $3.92 and a 52 week high of $21.71. The stock has a market capitalization of $286.63 million, a P/E ratio of -1.50 and a beta of 3.18.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, February 28th. The company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative net margin of 588.10% and a negative return on equity of 107.60%. On average, analysts predict that Karyopharm Therapeutics Inc will post -3.56 EPS for the current year.

In related news, insider Sharon Shacham sold 12,500 shares of the company’s stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $10.23, for a total value of $127,875.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ltd Chione sold 1,481,643 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total transaction of $7,126,702.83. The disclosure for this sale can be found here. Insiders sold 2,294,143 shares of company stock worth $11,246,578 over the last 90 days. 13.26% of the stock is currently owned by corporate insiders.

KPTI has been the topic of several research reports. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Thursday, January 10th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Monday, December 3rd. B. Riley initiated coverage on shares of Karyopharm Therapeutics in a report on Friday, November 30th. They issued a “buy” rating and a $23.00 price objective on the stock. BidaskClub upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 13th. Finally, ValuEngine upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 27th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $18.40.

TRADEMARK VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2019/03/17/citigroup-inc-has-1-23-million-position-in-karyopharm-therapeutics-inc-kpti.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Featured Article: What is a put option?

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.